A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis
NCT ID: NCT00769119
Last Updated: 2012-08-20
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
38 participants
INTERVENTIONAL
2008-09-30
2009-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AZD9668 active treatment
AZD9668
2 x 30 mg, oral tablet, twice daily for 28 days
AZD9668 placebo treatment
Placebo
2 x Matched placebo, oral tablet, twice daily for 28 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AZD9668
2 x 30 mg, oral tablet, twice daily for 28 days
Placebo
2 x Matched placebo, oral tablet, twice daily for 28 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical diagnosis of bronchiectasis
* Be sputum producers, with history of chronic expectoration on most days
Exclusion Criteria
* FEV1 of \<30% of predicted normal
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stockley, Prof
Role: PRINCIPAL_INVESTIGATOR
Queen Elizabeth Hospital, Birmingham, England
Carin Jorup
Role: STUDY_DIRECTOR
AstraZeneca R&D Lund
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Chemin Sainte-Foy, Quebec, Canada
Research Site
Calgary, , Canada
Research Site
Montreal, , Canada
Research Site
Ontario, , Canada
Research Site
Vancouver, , Canada
Research Site
Birmingham, , United Kingdom
Research Site
Cambridge, , United Kingdom
Research Site
London, , United Kingdom
Research Site
Newcastle, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Stockley R, De Soyza A, Gunawardena K, Perrett J, Forsman-Semb K, Entwistle N, Snell N. Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis. Respir Med. 2013 Apr;107(4):524-33. doi: 10.1016/j.rmed.2012.12.009. Epub 2013 Feb 20.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D0520C00010
Identifier Type: -
Identifier Source: org_study_id